|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The adverse impact of CYP2C19*2 polymorphisms was found not only in the risk of the presence of CHD, but also in the adverse cardiovascular events in CHD patients during the follow-up period of 14 months.
|
30868490 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
|
30403317 |
2019 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our preliminary results demonstrate that polymorphisms of genes encoding CYP2C subfamily represent potential genetic markers of CHD susceptibility.
|
28687336 |
2017 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).
|
28783717 |
2017 |
|
Coronary heart disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, the number and the type of coronary disease (thrombotic, fibrotic or both) did not differ between patients with different CYP2C19 enzyme activity.
|
28473221 |
2017 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the genotype frequencies of cytochrome P450, family2, subfamily C, polypeptide19 (CYP2C19); P2Y12 receptor; and glycoprotein IIIa polymorphisms in patients with coronary heart disease and their impact on clopidogrel responsiveness and major adverse cardiac events (MACEs).A total of 146 coronary heart disease patients of Han ethnicity, on a clopidogrel regimen, were enrolled.
|
27488401 |
2016 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare the clinical effects between individual antiplatelet therapy guided by CYP2C19 genetic testing and conventional dual antiplatelet therapy in patients with coronary artery disease after percutaneous coronary intervention.
|
26727381 |
2016 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.
|
25823779 |
2015 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
|
25891840 |
2015 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A breakdown analysis by age showed that the association of CYP2C19 rs12773342 with CHD was mainly found in individuals aged 55-65 (genotype: χ(2)=7.93, df=2, P=0.019; allele: χ(2)=4.45, df=1, P=0.035).
|
26054681 |
2015 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
|
26071277 |
2015 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
|
24402637 |
2014 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
α2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant.
|
24723553 |
2014 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
|
25008027 |
2014 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
|
25329996 |
2014 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
|
24535487 |
2014 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
|
24608794 |
2014 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.
|
23337798 |
2013 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this medium-size group of patients with stable CHD homozygous carriers of the loss-of-function allele CYP2C19*2 were at increased risk for subsequent CVD events during 8 year follow-up independent of other risk factors.
|
23981380 |
2013 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We screened patients with stable coronary artery disease for cytochrome P450 (CYP) 2C19 genotypes and enrolled 103 patients who lacked CYP2C19*2 or *3 loss-of-function allele to minimize the effect of this gene on high RPR.
|
23922147 |
2013 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data from six clinical studies demonstrated that carriers of the CYP2C19*17 variant had a marked protection against recurrent cardiovascular events in patients with coronary artery disease compared with non-carriers, as measured by a 16% decrease in the incidence of MACE (10.0% vs. 11.9%; OR, 0.82; 95% CI, 0.72-0.94; P = 0.005).
|
22123356 |
2012 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, carrier status for LOF CYP2C19 is associated with an increased risk of adverse clinical events in patients with coronary artery disease on clopidogrel therapy despite differences in clinical significance according to ethnicity.
|
22591668 |
2012 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
|
21693476 |
2012 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease.
|
22071359 |
2012 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We measured the CYP2C19 genotype and platelet aggregation in 201 patients with stable CHD.
|
21168310 |
2011 |